Lotus Pharmaceutical Co., Ltd.

1795

TW0001795003

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
323 ^TWD	-1.82%		+3.19%	+18.75%

Mar. 26	Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	CI
Mar. 14	Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director

March 26, 2024 at 06:38 am EDT

Lotus Pharmaceutical Co., Ltd. appointed Arni Hardarson as Representative of the Company's Institutional Director in place of Thor Kristjansson. Effective date of the new appointment is March 26, 2024.

Latest news about Lotus Pharmaceutical Co., Ltd.

Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	Mar. 26	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024	Jan. 31	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Jan. 14	CI
Transcript : Lotus Pharmaceutical Co., Ltd., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.	23-09-24	CI
Lotus Pharmaceutical Co., Ltd. Announces Director Changes	23-09-04	CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	23-08-15	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea	23-07-31	CI
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment	23-07-11	MT
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson	23-07-10	CI
Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members	23-07-10	CI
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023	23-06-16	CI
Lotus Pharmaceutical Co., Ltd. Announces Board Changes	23-06-15	CI
Lotus Pharmaceutical Co., Ltd. Announces Tenure Expiration of the Remuneration Committee Members	23-06-14	CI
Lotus Pharmaceutical Co., Ltd. Announces Change in Audit Committee Members	23-06-14	CI
Lotus Pharmaceutical Co., Ltd. Announces Change of Directors	23-06-14	CI
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101	23-06-05	CI
Lotus Pharmaceutical Co., Ltd. Approves to Enter, Jointly with Alvogen US, into an Exclusive Agreement with NeuroRx Inc. to Develop, Manufacture and Commercialize NRX-101	23-06-03	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
Lotus Pharmaceutical Co., Ltd. Receives Final Approval for its ANDA for Lenalidomide Capsules, 2.5 Mg and 20 Mg from US FDA	23-03-07	CI

Chart Lotus Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lotus Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

323 TWD

Average target price

390.2 TWD

Spread / Average Target

+20.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LOTUS PHARMACEUTICAL CO., LTD.	+18.75%	2.62B
ELI LILLY AND COMPANY	+33.74%	704B
NOVO NORDISK A/S	+28.36%	577B
JOHNSON & JOHNSON	-4.87%	348B
MERCK & CO., INC.	+17.60%	327B
ABBVIE INC.	+4.44%	288B
ASTRAZENECA PLC	+14.98%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-4.82%	147B

Other Pharmaceuticals